Arvinas (ARVN) Q4 2025 earnings review
Restructuring Secures Runway, But Commercial Limbo Looms
Arvinas closed out 2025 by demonstrating the effectiveness of its massive mid-year restructuring. Operating expenses are rapidly decelerating, driving a leaner organization with $685.4 million in cash that secures the runway into late 2028. However, revenue is sharply reversing, plunging to just $9.5 million in Q4 as legacy collaboration milestones dry up. The elephant in the room remains vepdegestrant: despite a looming FDA PDUFA date of June 5, 2026, the company still has not secured a third-party commercial partner after Pfizer backed away from co-commercialization. New CEO Randy Teel inherits a deeply funded early-stage pipeline but faces an immediate, critical execution test on the company's lead asset.
🐂 Bull Case
The Q2 2025 workforce reduction successfully curbed cash burn. With $685M in the bank, Arvinas can comfortably fund multiple Phase 1/1b clinical readouts (ARV-102, ARV-806, ARV-393) without the overhang of dilutive capital raises.
The early-stage oncology pipeline looks highly differentiated. ARV-806 demonstrated >40-fold higher potency in degrading KRAS G12D compared to a leading clinical-stage degrader, presenting a massive opportunity in solid tumors.
🐻 Bear Case
Pfizer's strategic withdrawal from vepdegestrant's commercialization leaves Arvinas completely dependent on finding a new partner. With the June 2026 PDUFA date closing in, the lack of a deal severely limits near-term revenue visibility.
With the Novartis technology transfer complete and Pfizer milestones adjusted, quarterly revenue dropped to just $9.5M. The company is now fully reliant on its cash reserves until a new BD deal is struck or a product is approved and launched.
⚖️ Verdict: ⚪
Neutral. Management successfully fixed the cost structure, providing ample time for the early-stage PROTAC pipeline to mature. However, the commercial uncertainty surrounding their only late-stage asset (vepdegestrant) capping potential upside until a partner is officially named.
Key Themes
Cost Cutting Strategy is Working
The strategic pivot announced earlier in 2025—which included cutting one-third of the workforce—is yielding clear results. GAAP R&D expenses are decelerating, down 27% YoY in Q4 to $61.1M, while G&A fell 33% to $23.0M. This discipline protects the balance sheet in a tough macroeconomic environment for biotech funding, ensuring the company can advance its wholly-owned pipeline independently.
The Vepdegestrant Clock is Ticking
Despite management touting 2025 as a 'truly transformative year', a glaring data point contradicts the positive momentum: the company still has no commercial partner for vepdegestrant. The FDA has assigned a PDUFA action date of June 5, 2026. If a capable third-party partner is not onboarded immediately, Arvinas risks a botched or delayed launch for the first-ever PROTAC degrader.
ARV-806 Shows Differentiated Potency
In the highly competitive KRAS G12D space, Arvinas is building a compelling case for ARV-806. Preclinical data presented at the AACR-NCI-EORTC conference showed >25-fold greater potency in reducing cancer cell proliferation versus clinical-stage inhibitors, and >40-fold higher potency than a comparable clinical-stage degrader. Fast enrollment in the Phase 1 trial validates physician interest.
Revenue Reversing as Legacy Partnerships Sunset
Revenue reversed sharply, plunging to $9.5 million in Q4 2025 from $59.2 million in Q4 2024. This was primarily due to the completion of technology transfers to Novartis in 2024 and reduced milestone recognition from the Pfizer vepdegestrant collaboration. Until vepdegestrant is approved or a new partnership is signed, Arvinas will operate with negligible top-line inflow.
Advancing BCL6 Combinations
ARV-393, the oral PROTAC BCL6 degrader, is showing promise beyond monotherapy. Preclinical data combining ARV-393 with glofitamab achieved 91% tumor growth inhibition with sequential dosing (versus 38% for the single agent). This provides a strong rationale for the planned combination cohort in the ongoing Phase 1 trial for diffuse large B-cell lymphoma (DLBCL).
Leadership Transition at a Critical Juncture
Randy Teel, Ph.D., has officially succeeded founding CEO John Houston. While telegraphed in previous quarters, changing the CEO just months before a pivotal FDA PDUFA date and amid active, high-stakes partnership negotiations introduces significant execution risk.
Other KPIs
Stable. The cash burn aligns with the company's restructuring goals. While substantial, it is comfortably covered by the $685.4 million cash hoard, justifying management's confidence in a runway extending into the second half of 2028.
Accelerating return of capital. Arvinas deployed nearly $92 million to buy back 10 million shares in 2025. This signals high internal conviction that the market is undervaluing the early-stage pipeline following the vepdegestrant setbacks.
Guidance
Stable. Management reiterated that current cash reserves are sufficient to fund operations into the second half of 2028, completely removing near-term financing risk.
Stable. The FDA review timeline is set, providing a hard deadline for the company to finalize a commercialization partnership.
Accelerating. Following data in Parkinson's disease, the company plans to push this neurodegenerative asset into progressive supranuclear palsy (PSP) trials in the first half of 2026, expanding the pipeline's CNS footprint.
Accelerating. The company's first immuno-oncology clinical candidate is on track to enter Phase 1 trials by mid-2026, adding another distinct modality to the clinical roster.
Key Questions
Vepdegestrant Partnership Timeline
With the June 5, 2026 PDUFA date fast approaching, what is the hard deadline for securing a commercial partner to ensure a seamless launch, and what contingency plans are in place if terms cannot be reached?
ARV-806 Clinical Data Expectations
Given the highlighted >40x preclinical potency advantage of ARV-806 over competitors, what specific early clinical markers of differentiation (e.g., safety profile, depth of degradation) are you prioritizing in the upcoming 2026 data readouts?
Strategic Vision Under New Leadership
With Randy Teel stepping in as CEO, how will the company's business development and M&A strategy shift, particularly regarding the balance between the oncology and rapidly growing neuroscience portfolios?